Psoriasis and Psoriatic Arthritis How to Treat in the Era of Biologics and Small Molecule Inhibitors?
Materialtyp:
ArtikelUtgivningsinformation: Basel MDPI - Multidisciplinary Digital Publishing Institute 2024Beskrivning: 1 electronic resource (166 p.)Innehållstyp: - text
- computer
- online resource
- 9783725818792
- 9783725818808
- Medicine
- Surgery
- 23
- BMDCs
- COVID-19
- IL-23
- IL-36γ
- Janus kinases
- Japan
- SARS-CoV-2
- Th17 cells
- adherence
- adipokines
- anti-IL-12
- anti-IL-17
- anti-TNF-α
- assessment
- autoantigens
- betamethasone dipropionate
- biological drugs
- biologics
- butyrate
- calcipotriol
- composite disease activity measures
- cross-sectional studies
- cytokines
- dendritic cell
- disease activity
- early diagnosis
- early intervention
- estrogen
- fatty acid-binding protein
- female sex hormone
- forkhead box protein 3
- glycoproteins
- gut microbiome
- health care surveys
- human
- inflammatory skin disease
- interleukin-17A
- interleukin-23
- long-term treatment
- metformin
- nail psoriasis
- patient-reported outcomes
- persistence
- proactive treatment
- progesterone
- psoriasis
- psoriatic arthritis
- regulatory T cell
- scalp psoriasis
- short chain fatty acid
- skin-resident memory T cells
- systemic therapy
- therapy
- topical therapy
- treatment
- treatment goal
- vitamin D3 derivatives
Open Access Unrestricted online access star
Psoriasis with psoriatic arthritis is a chronic and difficult-to-treat inflammatory skin condition. Recent developments in biology, immunology, and molecular biology have enabled us to use various targeted therapeutics in treating these conditions, such as biologics and small-molecule inhibitors. The enhanced speed at which translational research is developing in this field has led to the production of many biologics technologies and small-molecule inhibitors, but a complete cure for this condition has not yet been accomplished. In light of this, understanding the pathophysiology of these conditions is crucial and would allow us to carefully recognize which patients need to be treated earlier in order to improve patients' quality of life. This Special Issue is composed of discussions on the pathophysiology of psoriasis with psoriatic arthritis, including infiltrating effector T-cells, regulatory T-cells, dendritic cells, monocytes, and macrophages; the treatment of psoriasis with psoriatic arthritis, including biologics, small-molecule inhibitors, and topical treatments; and the quality of life of patients with this condition, which includes the introduction of treatment goals and the treat-to-target concept.
Creative Commons Licence cc by cc https://creativecommons.org/licenses/by/4.0/
eng
Freely available e-book